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Splenic artery pseudoaneurysms have been conventionally treated with surgical or endovascular techniques, including
transcatheter embolization. This case report describes the use of procoagulant components thrombin and collagen in
large volume to percutaneously embolize a giant splenic artery pseudoaneurysm. (J Vasc Surg 2004;40:574-7.)Visceral aneurysms are being diagnosed more fre-
quently and earlier in their natural course as a result of
advances in modern imaging methods. Splenic artery aneu-
rysms (SAA) are the most frequent type, accounting for
60% of all splanchnic artery aneurysms.1 Although giant
aneurysms, defined as greater than 2.5 cm in greatest
diameter, are rare, they have been reported.2
The major risk of SAAs and pseudoaneurysms is hem-
orrhage. Early literature demonstrated a falsely elevated risk
for rupture as a result of underdetection of SAAs. More
recent data suggest that the risk ranges from 3% to 10%, and
is higher for giant SAAs.3 The mortality rate after rupture
has been estimated at 10% to 25%.3,4 Hemorrhage from
splenic artery pseudoaneurysms has been reported in as
many as 37% of patients.5
Given the risk for rupture, guidelines recommend
resection of symptomatic SAAs, asymptomatic aneu-
rysms larger than 2.0 cm, and all pseudoaneurysms, to
avert rupture.6 Treatment options have consisted of
aneurysectomy, including splenectomy, particularly with
aneurysms located in the splenic hilum or distal third of
the artery, and angiographic embolization with coils or
gelatin sponge.7
We describe a giant splenic artery pseudoaneurysm
that was successfully treated with percutaneous injection
of a bovine thrombin-collagen compound (D-Stat Flow-
able Hemostat; Vascular Solutions Inc). This product is
a slight modification of the Duett sealing device indi-
cated for closure of femoral arterial puncture sites. In
February 2002 the D-Stat product was launched inde-
pendent of the sealing device. It is approved for manage-
ment and control of bleeding from vascular access sites,
percutaneous catheters and tubes, and tissue tract ooz-
ing. The procoagulant is a flowable mixture of thrombin,
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blood-clotting process by facilitating conversion of fi-
brinogen to a fibrin clot. D-Stat is not approved for
intravascular use.
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CASE REPORT
A 51-year-old man with a history of ethanol-induced chronic
pancreatitis had vague left upper quadrant pain. Endoscopic ultra-
sound scanning and abdominal computed tomography (CT) re-
vealed a giant splenic artery pseudoaneurysm (Fig 1, A).
Splenic arteriography demonstrated a tortuous splenic artery
and a 6.8  5.8-cm saccular distal splenic artery pseudoaneurysm
at the level of the splenic hilum (Fig 1, B). In addition to confirm-
ing the presence of the pseudoaneurysm, splenic angiography
revealed splenomegaly, occlusion of the splenic vein, and gastric
varices. Multiple attempts to selectively catheterize the tortuous
distal splenic artery in preparation for transcatheter embolization
were unsuccessful.
Ultrasound scanning was used to localize the aneurysm in the
left upper quadrant (Fig 1, C). With ultrasound guidance and with
the catheter in the proximal splenic artery for contrast material
injection under fluoroscopy, a 5F, 25-cm Ring needle (Cook, Inc)
was inserted into the pseudoaneurysm through a left anterior
midaxillary approach in the tenth interspace. Blood return and
contrast injection confirmed the intra-aneurysmal location of the
cannula.
The thrombin-collagen compound (D-Stat) was then in-
jected with a 10-mL syringe into the pseudoaneurysm in 5-mL
aliquots, for a total of 15 mL (40 mg/mL of collagen and 1000
U/mL of thrombin). After each injection, angiography and
ultrasound scanning were used to monitor for flow within the
pseudoaneurysm after waiting approximately 2 or 3 minutes.
Post-embolization splenic arteriograms and Doppler ultrasound
scans showed complete occlusion of the pseudoaneurysm,
which represented successful thrombosis (Fig 2, A and B). The
procedure was complicated by some showering of thrombotic
compound into the distal splenic bed, as seen on splenic arte-
riograms. The tract was embolized with the D-Stat compound
as the cannula was withdrawn from the pseudoaneurysm and
through the skin.
The patient tolerated the procedure well, with conscious
sedation with midazolam and fentanyl. He was admitted overnight
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and metronidazole therapy. The hematocrit remained stable, and
the patient was discharged the next day with a 1-week course of
levofloxacin, for prophylaxis against splenic abscess, given the
partial devascularization of the spleen. Follow-up Doppler ultra-
sound scans 3 weeks post-procedure demonstrated no flow within
the thrombosed pseudoaneurysm. At that time the spleen mea-
sured 11.4 cm, unchanged in length compared with pre-procedure
abdominal CT scans. Abdominal and pelvic CT scans 4 weeks
post-procedure demonstrated an ovoid area measuring 4.0  2.7
cm posterior to the thrombosed pseudoaneurysm, which was
thought to represent infarcted spleen. Several small linear splenic
infarcts were also seen in the periphery. One year after the proce-
dure, CT scans demonstrated interval decrease in size of the
thrombosed splenic artery pseudoaneurysm. The patient has re-
mained without symptoms.
Fig 2. A, Immediately after injection of compound, splenic arte-
riogram demonstrates complete occlusion of the pseudoaneurysm.
B, Post-injection ultrasound scan shows no flow within the pseu-
doaneurysm, representing thrombosis.Fig 1. A, Abdomen computed tomography scan demonstrates a
giant 6-cm splenic artery pseudoaneurysm just anterior to the spleen.
B, Arteriogram shows that the pseudoaneurysm is saccular and in-
volves the distal splenic artery. C, Doppler ultrasound scan shows
blood flow within the splenic artery pseudoaneurysm. Note presence
of mural thrombus.
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SAAs and splenic pseudoaneurysms are often clinically
occult and detected incidentally during radiologic exami-
nation. Common causes of SAA include medial degenera-
tion with superimposed atherosclerosis, mycosis, portal
hypertension, fibromuscular dysplasia, and congenital
anomalies. Pancreatic pseudoaneurysms result from arterial
wall digestion by pancreatic enzymes,8 and most com-
monly involve the splenic artery.3 They occur in 6% to 9.5%
of patients with chronic pancreatitis, with a greater than
90% mortality rate for untreated rupture.9
Cope et al10 introduced the concept of direct percu-
taneous injection of diluted thrombin for coagulation of
pseudoaneurysms of the iliac, femoral, and peroneal
arteries and a true aneurysm of an accessory hepatic
artery in 1986. Since that time, percutaneous thrombin
injection has also been used extensively in treating post-
catheterization femoral pseudoaneurysms.11 In 2000
Kemmeter et al12 described the use of percutaneous
thrombin injection for treatment of ruptured aneurysms
involving branches of the superior mesenteric artery.
More recently, Benjaminov et al13 published a report of
percutaneous thrombin injection of an intrarenal pseu-
doaneurysm. This procedure is of particular use when the
aneurysm artery cannot be selectively cannulated or em-
bolization with coils has failed.
Common complications of treating pseudoaneu-
rysms and visceral artery aneurysms angiographically in-
clude post-embolization fever and pain, due to splenic
infarction from migration of embolic material into non-
target arteries. In the literature this has been more
common with use of gelatin sponge, and is less likely
encountered with coils.3 Antibiotic therapy is also rec-
ommended, because infection and abscess formation are
possible complications.
The major complication in our patient was partial em-
bolization of the spleen. This was not thought to be clini-
cally significant in this patient with portal hypertension and
splenomegaly who has remained without symptoms. Fol-
low-up CT scans up to 1 year post-procedure demonstrated
near complete resolution of splenic infarcts. To avert this
initial complication smaller aliquots of D-Stat may have
been used with longer time intervals between injections.
Using a smaller syringe may have resulted in better control
of delivery of the compound.
The development of bovine thrombin-induced anti-
bodies is another possible complication of this procedure.
Because it contains small amounts of bovine factor V,
bovine thrombin has potential to elicit an immune response
in recipients by cross-reacting with human factor V, result-
ing in factor V deficiency. Streiff et al14 performed a review
of the MEDLINE database and identified 87 cases of
reported factor V antibody development in the last decade,
of which two thirds were related to bovine thrombin expo-
sure. Of these, 40% to 66% of patients who undergo cardiac
surgery and 20% of patients who undergo neurosurgerydeveloped bovine thrombin-associated factor V antibod-
ies.14
While percutaneous thrombin is commonplace for
treatment of femoral artery pseudoaneurysms, routine
intravascular use of thrombin-collagen for occlusion of
visceral aneurysms is not recommended. In this case the
tortuous course of the splenic artery made transcatheter
embolization and endovascular graft placement untena-
ble. Another alternative would have been to select the
splenic artery with a microcatheter through which de-
tachable coils could be used. Given the large size of the
pseudoaneurysm, the cost of coils would have exceeded
$1000. Proximal and distal coil transcatheter emboliza-
tion was considered technically impossible because the
standard coils large enough to occlude the vessel would
not pass through the microcatheter needed to navigate
the tortuous splenic artery. The use of thrombin alone
may also have led to therapeutic thrombosis of the
pseudoaneurysm, but the addition of collagen likely
potentiates coagulation. Stable thrombus was induced
within minutes of percutaneous thrombin-collagen in-
jection. However, long-term follow-up is imperative to
monitor for complications.
To our knowledge, this is the first reported case in
which a large volume of both thrombin and collagen (D-
Stat) have been introduced percutaneously into an unrup-
tured giant splenic artery pseudoaneurysm to successfully
establish thrombosis. The compound is currently marketed
to control tissue tract and topical bleeding. This case illus-
trates a new use of this device and highlights the growing
need for interventionalists to maintain flexibility in a rapidly
evolving field.
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